Article
Biochemistry & Molecular Biology
Monica M. Van Acker, Rebekah R. Schwartz, Kelly Andrews, Kristina Seiffert-Sinha, Animesh A. Sinha
Summary: This study found that blood relatives of AA patients show similar elevation of Th1 and Th17 pathway cytokines, suggesting a genetic basis for Th1 and Th17 dysregulation in AA. The elevation of Th17-related cytokines in an unrelated control individual may suggest predictive value.
Review
Rheumatology
E. Pelechas, P. V. Voulgari, A. A. Drosos
Summary: This report describes two cases of AA development associated with TNFα inhibitor biosimilar therapy, highlighting the need for physicians to be aware of potential immune skin reactions in patients receiving these medications.
RHEUMATOLOGY INTERNATIONAL
(2022)
Editorial Material
Medicine, General & Internal
Andrew Messenger, Matthew Harries
Summary: For many individuals, alopecia areata is a temporary issue with hair loss patches recovering spontaneously within a few months. However, for a significant portion of patients, this condition can persist long-term and progress to complete baldness, with limited chances of recovery. Severe cases of alopecia often do not respond to medical treatments, leaving patients to struggle with the challenges it presents.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Immunology
Xiao-Wen Huang, Huan-Xin Zheng, Meng-Lei Wang, Wan-Mei He, Mei-Xin Feng, Kang Zeng, Li Li
Summary: This retrospective study describes the successful use of the anti-TNF-alpha agent adalimumab in three cases of refractory livedoid vasculopathy and provides clinical evidence of its ability to improve skin lesions and relieve pain.
Review
Biochemistry & Molecular Biology
Fang-fang Dai, Min Hu, Yu-wei Zhang, Rong-hui Zhu, Li-ping Chen, Zhi-dian Li, Yan-jie Huang, Wei Hu, Yan-xiang Cheng
Summary: This study reviewed the effects of TNF-alpha disorder on pathological conditions during pregnancy and summarized the impact of anti-TNF-alpha drugs on adverse pregnancy outcomes. Intrauterine growth restriction, spontaneous abortion, and preterm birth were found to be the most common adverse pregnancy outcomes associated with anti-TNF-alpha drugs.
EXPERT REVIEWS IN MOLECULAR MEDICINE
(2022)
Article
Immunology
Fabien Francois, Loubna Naimi, Xavier Roblin, Anne-Emmanuelle Berger, Stephane Paul
Summary: The study evaluated the LISA-TRACKER assays for monitoring ABP501 and anti-ABP501 antibodies in human serum, showing that the assays are reliable and accurate. The results demonstrated the validity and consistency of using LISA-TRACKER for monitoring patients treated with ABP501.
Review
Medicine, General & Internal
Yi-qian Ma, Zhan Sun, Yu-Mei Li, Hui Xu
Summary: Alopecia areata (AA) is an autoimmune disease characterized by non-scarring hair loss. The exact pathogenesis of AA remains unclear, but immune privilege collapse, genetic predisposition, allergies, microbiota, and psychological stress are believed to play important roles. Oxidative stress is associated with AA and may trigger the collapse of hair follicle-immune privilege. Antioxidants may serve as a potential supplementary therapy for AA.
FRONTIERS IN MEDICINE
(2023)
Review
Immunology
Wen Xu, Sheng Wan, Bo Xie, Xiuzu Song
Summary: Alopecia areata (AA) is a non-scarring hair loss disorder caused by autoimmunity, but the exact functional mechanism remains unclear. Recent studies showed that immune-related cells and molecules affect AA through autocrine and paracrine signals mediated by various cytokines, chemokines, and growth factors. In addition, adipose-derived stem cells, gut microbiota, hair follicle melanocytes, non-coding RNAs, and specific regulatory factors play critical roles in intercellular communication, suggesting potential new targets for AA therapy. This review discusses the latest research on the possible pathogenesis and therapeutic targets of AA.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Microbiology
Zhiyu Liu, Xiaoyan Liu
Summary: Research has shown that there is a relationship between alopecia areata and the gut microbiome or metabolome, providing new directions for the prevention, clinical diagnosis, and treatment of this condition.
FRONTIERS IN MICROBIOLOGY
(2023)
Article
Dermatology
Brett A. King, Brittany G. Craiglow
Summary: JAK inhibitors have revolutionized the treatment of alopecia areata (AA), making it possible to treat moderate-to-severe cases that were previously refractory. This article provides a brief overview of the history of and rationale for JAK inhibitor treatment in AA, discusses phase 3 clinical trial data, and addresses considerations such as differences among JAK inhibitors, safety, and patient selection.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Review
Rheumatology
Ilaria Maccora, Eleonora Fusco, Edoardo Marrani, Athimalaipet Ramanan, Gabriele Simonini
Summary: This study summarized the evidence on the efficacy of anti-TNF alpha in childhood chronic uveitis, showing that adalimumab (ADA) was significantly superior to infliximab (INF) and etanercept (ETA) in treating this condition.
Article
Medicine, General & Internal
Brett King, Manabu Ohyama, Ohsang Kwon, Abraham Zlotogorski, Justin Ko, Natasha A. Mesinkovska, Maria Hordinsky, Yves Dutronc, Wen-Shuo Wu, Jill McCollam, Chiara Chiasserini, Guanglei Yu, Sarah Stanley, Katrin Holzwarth, Amy M. DeLozier, Rodney Sinclair
Summary: In two clinical trials, baricitinib treatment showed superiority in promoting hair regrowth in patients with severe alopecia areata, but longer trials are needed to evaluate its efficacy and safety.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Physiology
Gabriel Gomes Araujo, Rinaldo Rodrigues dos Passos Junior, Rosaline Rocha Lunardi, Gustavo Tadeu Volpato, Thaigra Sousa Soares, Fernanda Regina Giachini, Victor Vitorino Lima
Summary: This study evaluated the use of etanercept during pregnancy and found that it can cause harm to the fetus and placenta. However, further studies are needed to determine the appropriate dosage and potential risks.
FRONTIERS IN PHYSIOLOGY
(2022)
Article
Allergy
Emma Guttman-Yassky, Yael Renert-Yuval, Jennifer Bares, Margot Chima, Jason E. Hawkes, Patricia Gilleaudeau, Mary Sullivan-Whalen, Giselle K. Singer, Sandra Garcet, Ana B. Pavel, Mark G. Lebwohl, James G. Krueger
Summary: The study findings suggest that treatment of alopecia areata patients with Dupilumab can result in significant improvement, especially for patients with atopic dermatitis and high baseline IgE levels. Patient selection based on baseline serum IgE levels may enhance treatment outcomes.
Article
Medicine, General & Internal
Guillaume Larid, Guy Baudens, Alexis Dandurand, Pascal Coquerelle, Vincent Goeb, Marie Helene Guyot, Laurent Marguerie, Frederic Maury, Eric Veillard, Eric Houvenagel, Jean-Hugues Salmon, Rene-Marc Flipo, Elisabeth Gervais
Summary: This study compared the treatment retention of subcutaneous boDMARDs and bsDMARDs in different diseases, molecules, and lines of treatment. The results showed that bsDMARDs had significantly better retention than boDMARDs, especially for ETN and patients with RA. Citrated treatments demonstrated better retention.
FRONTIERS IN MEDICINE
(2022)